House Bill No. by Representative McFarland seeks to establish the Louisiana Early-Phase Clinical Trial Acceleration Framework by enacting Chapter 70 of Title 51 of the Louisiana Revised Statutes. This new chapter will include provisions for legislative findings, definitions, responsibilities of the Louisiana Economic Development department, participation requirements, performance benchmarks, reporting, confidentiality, and rulemaking. The framework aims to enhance patient access to investigational therapies, improve the speed and predictability of early-phase clinical trials, and attract private investment in Louisiana's biomedical innovation sector. All entities conducting covered clinical projects in Louisiana will be required to participate in the framework and enter into participation agreements with the department, which will outline expectations for benchmark categories and performance evaluation.

The bill also establishes confidentiality provisions to protect nonpublic business information and clarifies that it does not create warranties regarding site performance or patient outcomes. The Louisiana Economic Development department will oversee the implementation of the framework, ensuring compliance with established benchmarks and facilitating public reporting while safeguarding sensitive information. The legislation emphasizes that it will be executed within existing resources, without the need for new appropriations or positions, and mandates the department to submit an annual report to the legislature summarizing the performance of research entities and any barriers encountered.